OptiBiotix Health - Director/PDMR Shareholding

OptiBiotix Health

02/10/2025 07:00

RNS Number : 7141B

OptiBiotix Health PLC

02 October 2025

 

 

 

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Director/PDMR Shareholding

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, announces that the Company has been informed that David Blain, a Director of the Company, made the following purchase of ordinary shares in the capital of the Company. Further details are set out in the Notification of Dealing Form below.

 

Director
Purchase price
Ordinary shares purchased
Resultant interest in ordinary shares
Resultant percentage of issued ordinary shares
David Blain
11.75 pence
84,053
84,053
0.08%

 

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

 

OptiBiotix Health plc
www.optibiotix.com
Neil Davidson, Chairman
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD and Broker)
Tel: 020 7213 0880
Liam Murray / Ludovico Lazzaretti / James Western


 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
David Blain
2
Reason for notification
a.
Position/Status
Finance Director
b.
Initial notification/
Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
OptiBiotix Health Plc
b.
LEI
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

 Identification Code
Ordinary shares of 2p each
ISIN: GB00BP0RTP38
b.
Nature of the transaction
Purchase of ordinary shares
c.
Price(s) and volume(s)
Price(s) per share
Volume(s)
11.75 pence
84,053
d.
Aggregated information
- Volume
- Price
84,053 shares
11.75 pence per share
e.
Date of the transaction
1 October 2025
f.
Place of the transaction
London Alternative Market (AIMX)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHFSMFMFEISEDS